Frazier Life Sciences VIII SC 13D Beneficial ownership report

EXHIBIT A

AGREEMENT

Pursuant toRule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Arcutis Biotherapeutics, Inc.

Date: February 7, 2020	FRAZIER LIFE SCIENCES VIII, L.P.
	By FHM Life Sciences VIII, L.P., its general partner
	By FHM Life Sciences VIII, L.L.C., its general partner
	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer
Date: February 7, 2020	FHM LIFE SCIENCES VIII, L.P.
	By FHM Life Sciences VIII, L.L.C., its general partner
	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer
Date: February 7, 2020	FHM LIFE SCIENCES VIII, L.L.C.
	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer
Date: February 7, 2020	By:	*
		James N. Topper
Date: February 7, 2020	By:	*
		Patrick J. Heron
Date: February 7, 2020	*By:	/s/ Steve R. Bailey
		Steve R. Bailey, asAttorney-in-Fact

This Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.